510 related articles for article (PubMed ID: 26864464)
1. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.
Numakura T; Tamada T; Nara M; Muramatsu S; Murakami K; Kikuchi T; Kobayashi M; Muroi M; Okazaki T; Takagi S; Eishi Y; Ichinose M
BMC Pulm Med; 2016 Feb; 16():30. PubMed ID: 26864464
[TBL] [Abstract][Full Text] [Related]
2. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
3. Development of pulmonary sarcoidosis in Crohn's disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review.
Kashima S; Moriichi K; Ando K; Ueno N; Tanabe H; Yuzawa S; Fujiya M
BMC Gastroenterol; 2021 Oct; 21(1):373. PubMed ID: 34641810
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis during infliximab therapy for Crohn's disease.
Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Crohn's disease despite infliximab therapy.
Campos S; Coutinho I; Cardoso JC; Portela F
An Bras Dermatol; 2017; 92(5 Suppl 1):104-106. PubMed ID: 29267462
[TBL] [Abstract][Full Text] [Related]
6. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
7. An unusual cutaneous manifestation of Crohn's disease.
Weiser JA; Markowitz DM; Husain S; Grossman ME
Skinmed; 2011; 9(3):196-8. PubMed ID: 21675504
[TBL] [Abstract][Full Text] [Related]
8. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
[TBL] [Abstract][Full Text] [Related]
9. Intermittent Purpura Development Associated with Leukocytoclastic Vasculitis Induced by Infliximab for Crohn's Disease.
Kishimoto K; Kawashima K; Fukunaga M; Kotani S; Sonoyama H; Oka A; Mishima Y; Oshima N; Ishimura N; Ishikawa N; Maruyama R; Ishihara S
Intern Med; 2021 Feb; 60(3):385-389. PubMed ID: 32863363
[TBL] [Abstract][Full Text] [Related]
10. [IgA vasculitis associated with anti-TNF-α inhibitors in a patient with Crohn's disease].
Nishikawa J; Hosokawa A; Akashi M; Mihara H; Nanjo S; Yoshita H; Ando T; Kajiura S; Fujinami H; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2015 Oct; 112(10):1852-7. PubMed ID: 26440688
[TBL] [Abstract][Full Text] [Related]
11. Leukocytoclastic vasculitis complicating adalimumab therapy for Crohn's disease: Report of three cases.
Bernardes C; Carvalho D; Saiote J; Ramos J
Gastroenterol Hepatol; 2018; 41(7):442-443. PubMed ID: 29054318
[No Abstract] [Full Text] [Related]
12. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
14. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
16. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
[TBL] [Abstract][Full Text] [Related]
17. A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease-A Case Report.
Force BK; Vogel TP; Nguyen DM; Heck KA; Sebastian S; Takashima M; Yoshor D; Samson SL
Front Endocrinol (Lausanne); 2020; 11():350. PubMed ID: 32547497
[No Abstract] [Full Text] [Related]
18. Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine.
Sato K; Suga T; Hirayama A; Daikuhara S; Uehara T; Tanaka E
Clin J Gastroenterol; 2020 Feb; 13(1):1-5. PubMed ID: 31350718
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF treatment and miliary tuberculosis in Crohn's disease.
Milenković B; Dudvarski-Ilić A; Janković G; Martinović L; Mijac D
Srp Arh Celok Lek; 2011; 139(7-8):514-7. PubMed ID: 21980664
[TBL] [Abstract][Full Text] [Related]
20. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
